Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium

Pediatric Drugs

Volumn 18, Issue 4, 2016, Pages 303-318

  Gerlier, Laetitia ^a   Lamotte, Mark ^a   Dos Santos Mendes, Sofia ^b   Damm, Oliver ^c   Schwehm, Markus ^d   Eichner, Martin ^e,f  

^a IMS Health Real World Evidence Solutions   (Belgium)

^b ASTRAZENECA   (United Kingdom)

^c BIELEFELD UNIVERSITY   (Germany)

^d EXPLOSYS GMBH   (Germany)

^e UNIVERSITY OF TÜBINGEN   (Germany)

^f EPIMOS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; LIVE VACCINE;

ADOLESCENT; ADULT; ARTICLE; BASIC REPRODUCTION NUMBER; BELGIUM; CHILD; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG EFFICACY; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEASONAL INFLUENZA; INFLUENZA, HUMAN; INTRANASAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PROCEDURES; PUBLIC HEALTH; RISK; VACCINATION;

ADMINISTRATION, INTRANASAL; ADOLESCENT; BELGIUM; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PUBLIC HEALTH; RISK; VACCINATION; VACCINES, ATTENUATED;

EID: 84976428161     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-016-0180-6     Document Type: Article

References (67)

1. Haas J, Braun S, Wutzler P. Burden of influenza in Germany: a retrospective claims database analysis for the influenza season 2012/2013. Eur J Health Econ. 2015 (Epub 5 July 2015). doi:10.1007/s10198-015-0708-7.
2. Ehlken B, Anastassopoulou A, Hain J, Schröder C, Wahle K. Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany—results of a database analysis from May 2010 to April 2012. BMC Public Health. 2015;15:578.
3. McLaughlin JM, McGinnis JJ, Tan L, Mercatante A, Fortuna J. Estimated human and economic burden of four major adult vaccine-preventable diseases in the United States, 2013. J Prim Prev. 2015;36(4):259–73.
4. Crott R, Pouplier I, Roch I, Chen YC, Closon MC. Pneumonia and influenza, and respiratory and circulatory hospital admissions in Belgium: a retrospective database study. Arch Public Health. 2014;72(1):33.
5. Silva ML, Perrier L, Späth HM, Grog I, Mosnier A, Havet N, et al. Economic burden of seasonal influenza B in France during winter 2010–2011. BMC Public Health. 2014;14:56.
6. Plass D, Mangen MJ, Kraemer A, Pinheiro P, Gilsdorf A, Krause G, et al. The disease burden of hepatitis B, influenza, measles and salmonellosis in Germany: first results of the burden of communicable diseases in Europe study. Epidemiol Infect. 2014;142(10):2024–35.
7. Ambrose CS, Antonova EN. The healthcare and societal burden associated with influenza in vaccinated and unvaccinated European and Israeli children. Eur J Clin Microbiol Infect Dis. 2014;33(4):569–75.
8. Chow MY, Yin JK, Heron L, Morrow A, Dierig A, Booy R, et al. The impact of influenza-like illness in young children on their parents: a quality of life survey. Qual Life Res. 2014;23(5):1651–60.
9. Hollmann M, Garin O, Galante M, Ferrer M, Dominguez A, Alonso J. Impact of influenza on health-related quality of life among confirmed (H1N1) 2009 patients. PLoS One. 2013;8(3):e60477.
10. Pradas Velasco R, Villar FA, Puy Martínez-Zárate M. Use of European Quality of Life-5 Dimensions (EQ-5D) questionnary to value the health related quality of life variation because of influenza. Gac Sanit. 2009;23(2):104–8.
11. Bilcke J, Coenen S, Beutels P. Influenza-like-illness and clinically diagnosed flu: disease burden, costs and quality of life for patients seeking ambulatory care or no professional care at all. PLoS One. 2014;9(7):e102634.
12. Antonova EN, Rycroft CE, Ambrose CS, Heikkinen T, Principi N. Burden of paediatric influenza in Western Europe: a systematic review. BMC Public Health. 2012;12:968.
13. Fischer WA, Gong M, Bhagwanjee S, Sevransky J. Global burden of influenza as a cause of cardiopulmonary morbidity and mortality. Glob Heart. 2014;9(3):325–36.
14. WHO. Influenza (Seasonal). Fact sheet No. 211. March 2014. Available from: http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed 26 May 2016.
15. Hanquet G, Jonckheer P, Vlayen J, Vrijens F, Thiry N, Beutels P. Seasonal influenza vaccination: priority target groups—part 1. Good clinical practice (GCP). Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 162C D/2011/10273/452011. Available from: http://kce.fgov.be/publication/report/seasonal-influenza-vaccination-priority-target-groups-%E2%80%93-part-i#.V0btT_mLRhE. Accessed 26 May 2016.
16. Peltola V, Ziegler T, Ruuskanen O. Influenza A and B virus infections in children. Clin Infect Dis. 2003;36(3):299–305.
17. Poehling KA, Edwards KM, Griffin MR, Szilagyi PG, Staat MA, Iwane MK, et al. The burden of influenza in young children, 2004–2009. Pediatrics. 2013;131(2):207–16.
18. Johnson BF, Wilson LE, Ellis J, Elliot AJ, Barclay WS, Pebody RG, et al. Fatal cases of influenza A in childhood. PLoS One. 2009;4(10):e7671.
19. Wong KK, Jain S, Blanton L, Dhara R, Brammer L, Fry AM, et al. Influenza-associated pediatric deaths in the United States, 2004–2012. Pediatrics. 2013;132(5):796–804.
20. CDC. Seasonal influenza (flu) 2013. Available from: http://www.cdc.gov/flu/spotlights/children-flu-deaths.htm. Accessed 26 May 2016.
21. Santesso N, Hsu J, Mustafa R, Brozek J, Chen YL, Hopkins JP, et al. Antivirals for influenza: a summary of a systematic review and meta-analysis of observational studies. Influenza Other Respir Viruses. 2013;7(Suppl 2):76–81.
22. Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S. The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PLoS One. 2013;8(4):e60348.
23. CDC. Prevention—flu vaccine. CDC says “Take 3” actions to fight the flu. 2014. Available from: http://www.cdc.gov/flu/protect/preventing.htm. Accessed 26 May 2016.
24. Belgium.be. Informations et services officiels. Available from: http://www.belgium.be/fr/sante/risques_pour_la_sante/epidemies/grippe. Accessed 26 May 2016.
25. Pebody RG, Green HK, Andrews N, Zhao H, Boddington N, Bawa Z, et al. Uptake and impact of a new live attenuated influenza vaccine programme in England: early results of a pilot in primary school-age children, 2013/14 influenza season. Euro Surveill. 2014;19(22). pii: 20823.
26. Pebody RG, Green HK, Andrews N, Boddington NL, Zhao H, Yonova I, et al. Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. Euro Surveill. 2015;20(39). doi:10.2807/1560-7917.ES.2015.20.39.30029. pii:30029
27. WHO. Vaccines against influenza WHO position paper. WER November 20122012:461–76.
28. Loeb M, Russell ML, Moss L, Fonseca K, Fox J, Earn DJ, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA. 2010;303(10):943–50.
29. Glezen WP, Gaglani MJ, Kozinetz CA, Piedra PA. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis. 2010;202(11):1626–33.
30. Weycker D, Edelsberg J, Halloran ME, Longini IM, Nizam A, Ciuryla V, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine. 2005;23(10):1284–93.
31. Vynnycky E, Pitman R, Siddiqui R, Gay N, Edmunds WJ. Estimating the impact of childhood influenza vaccination programmes in England and Wales. Vaccine. 2008;26(41):5321–30.
32. Pitman RJ, White LJ, Sculpher M. Estimating the clinical impact of introducing paediatric influenza vaccination in England and Wales. Vaccine. 2012;30(6):1208–24.
33. Pitman RJ, Nagy LD, Sculpher MJ. Cost-effectiveness of childhood influenza vaccination in England and Wales: results from a dynamic transmission model. Vaccine. 2013;31(6):927–42.
34. Pitman R, Fisman D, Zaric GS, Postma M, Kretzschmar M, Edmunds J, et al. Dynamic transmission modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–5. Value Health. 2012;15(6):828–34.
35. Baguelin M, Flasche S, Camacho A, Demiris N, Miller E, Edmunds WJ. Assessing optimal target populations for influenza vaccination programmes: an evidence synthesis and modelling study. PLoS Med. 2013;10(10):e1001527.
36. Rose MA, Damm O, Greiner W, Knuf M, Wutzler P, Liese JG, et al. The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. BMC Infect Dis. 2014;14:40.
37. Damm O, Eichner M, Rose MA, Knuf M, Wutzler P, Liese JG, et al. Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. Eur J Health Econ. 2015;16(5):471–88.
38. Gerlier L, Weil-Olivier C, Carrat F, Lenne X, Greneche S, Lamotte M, et al. Public health and economic impact of vaccinating children with a quadrivalent live attenuated influenza vaccine in France using a dynamic transmission model. In: ISPOR 17th Annual European Congress: Amsterdam; 2014.
39. StatBel. Statistics Belgium. SPF/FOD Economie. Available from: http://statbel.fgov.be/en/statistics/figures/. Accessed 26 May 2016.
40. Weil-Olivier C, Lina B. Vaccination coverage with seasonal and pandemic influenza vaccines in children in France, 2009–2010 season. Vaccine. 2011;29(40):7075–9.
41. ISP/WIV. Belgian Health Interview Survey (HIS)—interactive analysis. Available from: https://hisia.wiv-isp.be/SitePages/Home.aspx. Accessed 26 May 2016.
42. Mossong J, Hens N, Jit M, Beutels P, Auranen K, Mikolajczyk R, et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med. 2008;5(3):e74.
43. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167(7):775–85.
44. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20(2):127–33.
45. Heikkinen T, Silvennoinen H, Peltola V, Ziegler T, Vainionpaa R, Vuorinen T, et al. Burden of influenza in children in the community. J Infect Dis. 2004;190(8):1369–73.
46. WHA (World Health Assembly). Prevention and control of influenza pandemics and annual epidemics, 56th World Health Assembly. Geneva: World Health Organisation; 2003.
47. Tuppin P, Samson S, Weill A, Ricordeau P, Allemand H. Influenza vaccination coverage in France in 2007–2008: contribution of vaccination refund data from the general health insurance scheme. Med Mal Infect. 2009;39(10):780–8.
48. Jefferson T, Rivetti A, Harnden A, Di Pietrantonj C, Demicheli V. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev. 2008;(2):CD004879.
49. Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine. 2009;27(7):1101–10.
50. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009;361(13):1260–7.
51. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, Thomas RE. Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev. 2010(2):CD004876.
52. Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J. 2010;29(9):806–11.
53. Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine. 2015;33(1):246–51.
54. Tam JS, Capeding MR, Lum LC, Chotpitayasunondh T, Jiang Z, Huang LM, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J. 2007;26(7):619–28.
55. Beutels P, Vandendijck Y, Willem L, Goeyvaerts N, Blommaert A, Van Kerckhove K, et al. Seasonal influenza vaccination: prioritizing children or other target groups? Part II: cost-effectiveness analysis. Health Technology Assessment (HTA) Brussels: Belgian Health Care Knowledge Centre (KCE). KCE Reports 204. 2013. Available from: https://kce.fgov.be/fr/publication/report/vaccination-contre-la-grippe-saisonni%C3%A8re-priorit%C3%A9-aux-enfants-ou-%C3%A0-d%E2%80%99autres-group#.V0btlPmLRhE. Accessed 26 May 2016.
56. Prosser LA, Meltzer MI, Fiore A, Epperson S, Bridges CB, Hinrichsen V, Lieu TA. Effects of adverse events on the projected population benefits and cost-effectiveness of using live attenuated influenza vaccine in children aged 6 months to 4 years. Arch Pediatr Adolesc Med. 2011;165(2):112–8. doi:10.1001/archpediatrics.2010.182.
57. Rajaram S, Blak B, Steffey A, Caspard H. Impact of universal versus targeted vaccination policy on childhood influenza vaccination rates in children with asthma in the United Kingdom. Abstract ESPID-0471 presented at the 33rd Annual Meeting of the European Society for Paediatric Infectious Diseases, Leipzig, 12–16 May 2015.
58. Sreenivasan MV, He HH, Park SY. Administration time between seasonal live-attenuated influenza vaccine and trivalent influenza vaccine during the “Stop Flu at School” Campaign-Hawaii, 2009. Public Health Rep. 2014;129(3):229–36.
59. Flood EM, Block SL, Hall MC, Rousculp MD, Divino VM, Toback SL, Mahadevia PJ. Children’s perceptions of influenza illness and preferences for influenza vaccine. J Pediatr Health Care. 2011;25(3):171–9. doi:10.1016/j.pedhc.2010.04.007.
60. Kwong JC, Pereira JA, Quach S, Pellizzari R, Dusome E, Russell ML, et al. Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Program Delivery and Evaluation Group. Randomized evaluation of live attenuated vs. inactivated influenza vaccines in schools (RELATIVES) pilot study: a cluster randomized trial. Vaccine. 2015;33(4):535–41. doi:10.1016/j.vaccine.2014.11.044.
61. Block SL, Toback SL, Yi T, Ambrose CS. Efficacy of a single dose of live attenuated influenza vaccine in previously unvaccinated children: a post hoc analysis of three studies of children aged 2 to 6 years. Clin Ther. 2009;31(10):2140–7.
62. Department of Health. Summary of JCVI consideration of the number of doses of influenza vaccine for influenza vaccine-naïve children, March-April 2013. Published 26 July 2013. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/225425/JCVI_summary_-_number_doses_flu_vaccine_-_final.pdf. Accessed 26 May 2016.
63. Carrat F, Valleron AJ. Influenza mortality among the elderly in France, 1980–90: how many deaths may have been avoided through vaccination? J Epidemiol Community Health. 1995;49(4):419–25.
64. HAS. Fluenz—Avis de la Commission de Transparence du 18 juillet 2012. 18 Juillet 2012. Available from: http://www.has-sante.fr/portail/jcms/c_1284808/en/fluenz. Accessed 26 May 2016.
65. SPILF. Société de Pathologie Infectieuse de Langue Française (SPILF): Prise en charge de la grippe en dehors d’une situation de pandémie en 2005—Texte Long. Médecine et maladies infectieuses 35 (2005). p. S237–244. doi:10.1016/j.medmal.2005.09.001.
66. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, Schmitt HJ, et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med. 2011;365(15):1406–16.
67. Meier CR, Napalkov PN, Wegmüller Y, Jefferson T, Jick H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. Eur J Clin Microbiol Infect Dis. 2000;19(11):834–42.